ContextPhysical activity has been shown to decrease the incidence of breast cancer, but the effect on recurrence or survival after a breast cancer
An abstract is unavailable.doi:10.1097/01.COT.0000287788.87212.92SusmanEdOncology Times
Dr. Stegall says, “Breast cancer more commonly spreads to the chest before going to the brain. “Triple negative and HER2 positive breast cancer spreads to the brain more often than hormone positive breast cancer does.” My relative’s bone mets were finally discovered on an X-ray for uppe...
To identify patients with multiple Mets, we compared the dataset using the Venn diagram. The Venn diagram indicates 35 medical records intersecting between "metas" and Liver, 9 medical records intersecting between "metas" and Bone, 6 medical records intersecting between "metas" and Brain, and 27...
progression. Expression of RANKL, RANK, and OPG has been detected in breast cancer cell lines and in human primary breast cancers. To date, dysregulation of RANKL/RANK/OPG system at the skeletal level has been widely documented in the context of metastatic bone disease. In fact, RANKL inhibiti...
That means, in case you missed it - he thinks I could be cured. I could be one of the .00005% of people (or whatever) with mets who actually don't die of it. Or, at least, don't die soon - the five year survival rate jumps to 40%, according to one study, and I don't ...
TRPV4 expression with respect to DMFS and breast cancer subtype were also analyzed using KMplotter (http://kmplot. com/analysis/) and GeneAnalytics (http://geneanalytics.duhs.duke. edu/index.html), respectively. The former incorporated the gene expression data and survival information from GEO ...
T-DXd Shows Promise in Treating HER2+ Breast Cancer With Brain Mets Ovarian Function Suppression Improves Survival in Premenopausal Women with HR+, HER2+ Breast Cancer A Closer Look at T-DXd in HER2-Positive Breast Cancer Navigating Treatment Options for HER2+ BC: A Need for Customization ...
cancer, reduced blood clot formation, as well as a prolonged disease-free survival [40] time to recurrence and time to distant recurrence when compared to tamoxifen [44,45], representing the recommended standard therapy for post-menopausal women with ER-positive breast cancer nowadays [43,44]. ...
Importantly, fulvestrant enhanced the self-renewal (growth as secondary MS) of the HTR-Bone-Mets, which was abrogated with the addition of tocilizumab (Fig. 2e,f and Supplementary Fig. 3f). IL6R blockade increases ER and reduces Stat3/Notch3/CD133. To determine whether HT-resistant metastases...